DRUGS & SUPPLEMENTS
How often in a day do you take medicine? How many times?
Granisetron® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.
Granisetron is a serotonin -3 (5-HT3) receptor antagonist indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days. (1)
The transdermal system should be applied to clean, dry, intact healthy skin on the upper outer arm. Granisetron should not be placed on skin that is red, irritated, or damaged.
Each patch is packed in a pouch and should be applied directly after the pouch has been opened.
The patch should not be cut into pieces.
Apply a single transdermal system (patch) to the upper outer arm a minimum of 24 hours before chemotherapy. The patch may be applied up to a maximum of 48 hours before chemotherapy as appropriate. Remove the patch a minimum of 24 hours after completion of chemotherapy. The patch can be worn for up to 7 days depending on the duration of the chemotherapy regimen. (2)
Apply a single patch to the upper outer arm a minimum of 24 hours before chemotherapy. The patch may be applied up to a maximum of 48 hours before chemotherapy as appropriate. Remove the patch a minimum of 24 hours after completion of chemotherapy. The patch can be worn for up to 7 days depending on the duration of the chemotherapy regimen.
Granisetron is a 52 cm2 patch containing 34.3 mg of Granisetron. The patch releases 3.1 mg of Granisetron per 24 hours for up to 7 days.
Transdermal System: 52 cm2 patch containing 34.3 mg of Granisetron delivering 3.1 mg per 24 hours (3)
Granisetron is contraindicated in patients with known hypersensitivity to Granisetron or to any of the components of the patch.
Known hypersensitivity to Granisetron or to any of the components of the patch (4)
The use of Granisetron in patients may mask a progressive ileus and/or gastric distention caused by the underlying condition.
The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs, serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of another 5-HT3 receptor antagonist alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia care unit or an infusion center.
Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Granisetron and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue Granisetron and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if Granisetron is used concomitantly with other serotonergic drugs. .
In clinical trials with Granisetron, application site reactions were reported that were generally mild in intensity and did not lead to discontinuation of use. The incidence of reactions was comparable with placebo.
If severe reactions, or a generalized skin reaction occur (e.g., allergic rash, including erythematous, macular, papular rash or pruritus), the patch must be removed.
A heat pad should not be applied over or in vicinity of Granisetron patch. Patients should avoid prolonged exposure to heat as plasma concentration continues increasing during the period of heat exposure .
Granisetron may be affected by direct natural or artificial sunlight. Patients must be advised to cover the patch application site, e.g. with clothing, if there is a risk of exposure to sunlight throughout the period of wear and for 10 days following its removal because of a potential skin reaction .
The most common adverse reaction is constipation. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Kyowa Kirin, Inc. at 1-800-SANCUSO (1-800-726-2876) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of Granisetron was evaluated in a total of 404 patients undergoing chemotherapy who participated in two double-blind, comparator studies with patch treatment durations of up to 7 days. The control groups included a total of 406 patients who received a daily dose of 2 mg oral Granisetron, for 1 to 5 days.
Adverse reactions occurred in 8.7% (35/404) of patients receiving Granisetron and 7.1% (29/406) of patients receiving oral Granisetron. The most common adverse reaction was constipation that occurred in 5.4% of patients in the Granisetron group and 3.0% of patients in the oral Granisetron group.
Table 1 lists the adverse reactions that occurred in at least 3% of patients treated with Granisetron or oral Granisetron.
|Body System |
|Granisetron TDS |
|Oral Granisetron |
|Nervous system disorders|
5-HT3 receptor antagonists, such as Granisetron, may be associated with arrhythmias or ECG abnormalities. Three ECGs were performed on 588 patients in a randomized, parallel group, double-blind, double-dummy study: at baseline before treatment, the first day of chemotherapy, and 5 to 7 days after starting chemotherapy. QTcF prolongation greater than 450 milliseconds was seen in a total of 11 (1.9%) patients after receiving Granisetron, 8 (2.7%) on oral Granisetron, and 3 (1.1%) on the patch. No new QTcF prolongation greater than 480 milliseconds was observed in any patient in this study. No arrhythmias were detected in this study.
Adverse reactions reported in clinical trials with other formulations of Granisetron include the following:
Gastrointestinal: abdominal pain, diarrhea, constipation, elevation of ALT and AST levels, nausea and vomiting
Cardiovascular: hypertension, hypotension, angina pectoris, atrial fibrillation and syncope have been observed rarely
Central Nervous System: dizziness, insomnia, headache, anxiety, somnolence and asthenia
Hypersensitivity: rare cases of hypersensitivity reactions, sometimes severe (e.g. anaphylaxis, shortness of breath, hypotension, urticaria) have been reported
Other: fever; events often associated with chemotherapy have also been reported: leucopenia, decreased appetite, anemia, alopecia, thrombocytopenia.
The following adverse reactions have been identified during post approval use of Granisetron. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
General Disorders and Administration Site Conditions: Application site reactions (pain, pruritus, erythema, rash, irritation, vesicles, burn, discoloration, urticaria); patch non-adhesion.
Cardiac Disorders: bradycardia, chest pain, palpitations, sick sinus syndrome
Granisetron does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system in vitro. There have been no definitive drug-drug interaction studies to examine pharmacokinetic or pharmacodynamic interaction with other drugs. However, in humans, Granisetron hydrochloride injection has been safely administered with drugs representing benzodiazepines, neuroleptics and anti-ulcer medications commonly prescribed with antiemetic treatments. Granisetron hydrochloride injection also does not appear to interact with emetogenic cancer therapies. In agreement with these data, no clinically relevant drug interactions have been reported in clinical studies with Granisetron.
Because Granisetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP1A1 and CYP3A4), inducers or inhibitors of these enzymes may change the clearance and hence, the half-life of Granisetron. In addition, the activity of the cytochrome P-450 subfamily 3A4 (involved in the metabolism of some of the main narcotic analgesic agents) is not modified by Granisetron hydrochloride in vitro. In in vitro human microsomal studies, ketoconazole inhibited ring oxidation of Granisetron hydrochloride. However, the clinical significance of in vivo pharmacokinetic interactions with ketoconazole is not known. In a human pharmacokinetic study, hepatic enzyme induction with phenobarbital resulted in a 25% increase in total plasma clearance of intravenous Granisetron hydrochloride. The clinical significance of this change is not known.
Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) .
No clinically relevant drug interactions have been reported in clinical studies with Granisetron. (7)
Pregnancy Category B
Reproduction studies with Granisetron hydrochloride have been performed in pregnant rats at intravenous doses up to 9 mg/kg/day (54 mg/m2/day, about 24 times the recommended human dose delivered by the Granisetron patch, based on body surface area) and oral doses up to 125 mg/kg/day (750 mg/m2/day, about 326 times the recommended human dose with Granisetron based on body surface area). Reproduction studies have been performed in pregnant rabbits at intravenous doses up to 3 mg/kg/day (36 mg/m2/day, about 16 times the human dose with Granisetron based on body surface area) and at oral doses up to 32 mg/kg/day (384 mg/m2/day, about 167 times the human dose with Granisetron based on body surface area). These studies did not reveal any evidence of impaired fertility or harm to the fetus due to Granisetron. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Granisetron should be used during pregnancy only if clearly needed.
It is not known whether Granisetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Granisetron is administered to a nursing woman.
Safety and effectiveness of Granisetron have not been established in pediatric patients.
Clinical studies of Granisetron did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, cautious treatment selection for an elderly patient is prudent because of the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Although no studies have been performed to investigate the pharmacokinetics of Granisetron in patients with renal or hepatic impairment, pharmacokinetic information is available for intravenous Granisetron .
There is no specific antidote for Granisetron overdosage. In the case of overdosage, symptomatic treatment should be given.
Overdosage of up to 38.5 mg of Granisetron hydrochloride, as a single intravenous injection, has been reported without symptoms or only the occurrence of a slight headache.
In clinical trials there were no reported cases of overdosage with Granisetron.
Granisetron contains Granisetron, which is a serotonin-3 (5-HT3) receptor antagonist. Chemically it is 1-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide with a molecular weight of 312.4. Its empirical formula is C18H24N4O, while its chemical structure is:
Granisetron is a white to off-white solid that is insoluble in water. Granisetron is a thin, translucent, matrix-type transdermal patch that is rectangular-shaped with rounded corners, consisting of a backing, the drug matrix and a release liner.
Granisetron is a selective 5-hydroxytryptamine3 receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT1, 5-HT1A, 5-HT1B/C, 5-HT2; for alpha1-, alpha2-, or beta-adrenoreceptors; for dopamine-D2; or for histamine-H1; benzodiazepine; picrotoxin or opioid receptors.
Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT3 receptors, Granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferret animal model, a single Granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds.
The effect of Granisetron on QTc prolongation was evaluated in a randomized, single-blind, positive (moxifloxacin 400 mg) - and placebo controlled parallel study in healthy subjects. A total of 120 subjects were administered Granisetron patch (n=60) or intravenous Granisetron (10 mcg/kg over 30 seconds; n=60). In a study with demonstrated ability to detect small effects, the upper bound of the 90% confidence interval for the largest placebo adjusted, baseline corrected QTc based on Fridericia correction method (QTcF) for Granisetron was below 10 ms. This study suggests that Granisetron does not have significant effects on QT prolongation.
No evidence of an effect on plasma prolactin or aldosterone concentrations has been found in studies using Granisetron.
The effect on oro-cecal transit time following application of Granisetron has not been studied. Granisetron hydrochloride injection exhibited no effect on oro-cecal transit time in healthy subjects given a single intravenous infusion of 50 mcg/kg or 200 mcg/kg. Single and multiple oral doses of Granisetron hydrochloride slowed colonic transit in healthy subjects.
Granisetron crosses intact skin into the systemic circulation by a passive diffusion process.
Following a 7-day application of Granisetron in 24 healthy subjects, high inter-subject variability in systemic exposure was observed. Maximal concentration was reached at approximately 48 hours (range: 24-168 hours) following patch application. Mean Cmax was 5.0 ng/mL (CV: 170%) and mean AUC0-168hr was 527 ng-hr/mL (CV: 173%).
|Mean Plasma Concentration of Granisetron (mean ± SD)|
Based on the measure of residual content of the patch after removal, approximately 66% (SD: ± 10.9) of Granisetron is delivered following patch application for 7 days.
Following consecutive application of two Granisetron patches, each for seven days, Granisetron levels were maintained over the study period with evidence of minimal accumulation. The mean plasma concentration at 24 hours after the second patch application was 1.5-fold higher due to residual Granisetron from the first patch. As the plasma concentration increased after the second patch application, the difference decreased and the mean plasma concentration at 48 hours was 1.3-fold higher after the second patch compared to that after the first patch.
In a study designed to assess the effect of heat on the transdermal delivery of Granisetron from Granisetron in healthy subjects, a heat pad generating an average temperature of 42°C (107.6°F) was applied over the patch for 4 hours each day over the 5 day period of wear. The application of the heat pad was associated with an increase in plasma Granisetron concentrations during the period of heat pad application. The elevated plasma concentration declined after removal of the heat pad. Mean Cmax with intermittent heat exposure was 6% higher than without heat. Mean partial AUCs over 6 hours with 4 hour of heat application (AUC0-6, AUC24-30, and AUC48-54) were 4.9, 1.4, and 1.1 folds higher, respectively, with heat pad than without heat pad. A heat pad should not be applied over or in the near vicinity of the Granisetron patch.
Plasma protein binding is approximately 65%. Granisetron distributes freely between plasma and red blood cells.
Granisetron metabolism involves N-demethylation and aromatic ring oxidation followed by conjugation. In vitro liver microsomal studies show that granisetron's major route of metabolism is inhibited by ketoconazole, suggestive of metabolism mediated by the cytochrome P-450 3A subfamily. Animal studies suggest that some of the metabolites may also have 5-HT3 receptor antagonist activity.
Clearance is predominantly by hepatic metabolism. Based on a study with intravenous injection, approximately 12% of the dose is excreted unchanged in the urine of healthy subjects in 48 hours. The remainder of the dose is excreted as metabolites, 49% in the urine, and 34% in the feces.
There is evidence to suggest that female subjects had higher Granisetron concentrations than males following patch application. However, no statistically significant difference in clinical efficacy outcome was observed between genders.
No studies have been performed to investigate the pharmacokinetics of Granisetron in pediatrics.
Following application of Granisetron patch in healthy subjects, mean AUC0-z, Cmax, and Cavg were 17%, 15%, and 16% higher, respectively in male and female elderly subjects (≥ 65 years) compared to younger subjects (aged 18-45 years inclusive). These pharmacokinetic parameters were largely overlapped between the two age groups with high variability (CV: >50%).
Following a single 40 mcg/kg intravenous dose of Granisetron hydrochloride in elderly volunteers (mean age 71 years), lower clearance and longer half-life were observed compared to younger healthy volunteers.
Total clearance of Granisetron was not affected in patients with severe renal failure who received a single 40 mcg/kg intravenous dose of Granisetron hydrochloride.
In patients with hepatic impairment due to neoplastic liver involvement, total plasma clearance following a single 40 mcg/kg intravenous dose of Granisetron hydrochloride was approximately halved compared to patients without hepatic impairment. Given the wide variability in pharmacokinetic parameters of Granisetron and the good tolerance of doses well above the recommended dose, dose adjustment in patients with hepatic functional impairment is not necessary.
Body Mass Index
In a clinical study designed to assess Granisetron exposure from Granisetron in subjects with differing levels of body fat, using body mass index (BMI) as a surrogate measure for subcutaneous fat, no significant differences were seen in the plasma pharmacokinetics of Granisetron in male and female subjects with low BMI [<19.5 kg/m2 (males), <18.5 kg/m2 (females)] and high BMI (30.0 to 39.9 kg/m2 inclusive) compared to a control group (BMI 20.0 to 24.9 kg/m2 inclusive).
The pharmacokinetic profile of Granisetron from Granisetron was assessed in healthy Japanese males. Following the application of a single 6-day Granisetron 52 cm2, in healthy male Japanese subjects, mean Cmax, AUC(0-144), and AUC(0-∞) values were 5.02 ng/mL (CV: 66%), 492 ng.hr/mL (CV: 72%), and 562 ng.hr/mL (CV: 60%), respectively, and a median tmax value was 48 hours.
In a 24-month carcinogenicity study, rats were treated orally with Granisetron 1, 5 or 50 mg/kg/day. The 50 mg/kg/day dose was reduced to 25 mg/kg/day (150 mg/m2/day) during week 59 due to toxicity. For a 50 kg person of average height (1.46 m2 body surface area), these doses represent about 2.6, 13, and 65 times the recommended clinical dose (3.1 mg/day, 2.3 mg/m2/day, delivered by the Granisetron patch, on a body surface area basis). There was a statistically significant increase in the incidence of hepatocellular carcinomas and adenomas in males treated with 5 mg/kg/day (30 mg/m2/day, about 13 times the recommended human dose with Granisetron, on a body surface area basis) and above, and in females treated with 25 mg/kg/day (150 mg/m2/day, about 65 times the recommended human dose with Granisetron, on a body surface area basis). No increase in liver tumors was observed at a dose of 1 mg/kg/day (6 mg/m2/day, about 2.6 times the recommended human dose with Granisetron, on a body surface area basis) in males and 5 mg/kg/day (30 mg/m2/day, about 13 times the recommended human dose with Granisetron, on a body surface area basis) in females.
In a 12-month oral toxicity study, treatment with Granisetron 100 mg/kg/day (600 mg/m2/day, about 261 times the recommended human dose with Granisetron, on a body surface area basis) produced hepatocellular adenomas in male and female rats while no such tumors were found in the control rats. A 24-month mouse carcinogenicity study of Granisetron did not show a statistically significant increase in tumor incidence, but the study was not conclusive.
Because of the tumor findings in rat studies, Granisetron should be prescribed only at the dose and for the indication recommended .
Granisetron was not mutagenic in an in vitro Ames test and mouse lymphoma cell forward mutation assay, and in vivo mouse micronucleus test and in vitro and ex vivo rat hepatocyte UDS assays. It, however, produced a significant increase in UDS in HeLa cells in vitro and a significant increased incidence of cells with polyploidy in an in vitro human lymphocyte chromosomal aberration test.
Granisetron at subcutaneous doses up to 6 mg/kg/day (36 mg/m2/day, about 16 times the recommended human dose of Granisetron, on a body surface area basis), and oral doses up to 100 mg/kg/day (600 mg/m2/day, about 261 times the recommended human dose of Granisetron, on a body surface area basis) was found to have no effect on fertility and reproductive performance of male and female rats.
When tested for potential photogenotoxicity in vitro in a Chinese hamster ovary (CHO) cell line, at 200 and 300 mcg/mL, Granisetron increased the percentage of cells with chromosomal aberration following photoirradiation.
Granisetron was not phototoxic when tested in vitro in a mouse fibroblast cell line. When tested in vivo in guinea-pigs, Granisetron patches did not show any potential for photoirritation or photosensitivity. No phototoxicity studies have been performed in humans.
The effectiveness of Granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) was evaluated in a randomized, parallel group, double-blind, double-dummy study conducted in the U.S. and abroad. The study compared the efficacy, tolerability and safety of Granisetron with that of 2 mg oral Granisetron once daily in the prevention of nausea and vomiting in a total of 641 patients receiving multi-day chemotherapy.
The population randomized into the trial included 48% males and 52% females aged 16 to 86 years receiving moderately emetogenic (ME) or highly emetogenic (HE) multi-day chemotherapy. Seventy-eight (78%) of patients were White, 12% Asian, 10% Hispanic/Latino and 0% Black.
The Granisetron patch was applied 24 to 48 hours before the first dose of chemotherapy, and kept in place for 7 days. Oral Granisetron was administered daily for the duration of the chemotherapy regimen, 1 hour before each dose of chemotherapy. Efficacy was assessed from the first administration until 24 hours after the start of the last day's administration of the chemotherapy regimen.
The primary endpoint of the trial was the proportion of patients achieving no vomiting and/or retching, no more than mild nausea and no rescue medication from the first administration until 24 hours after the start of the last day's administration of multi-day chemotherapy. Using this definition, the effect of Granisetron was established in 60.2% of patients in the Granisetron arm and 64.8% of patients receiving oral Granisetron (difference -4.89%; 95% confidence interval –12.91% to +3.13%).
An assessment of patch adhesion in 621 patients receiving either active or placebo patches showed that less than 1% of patches became detached over the course of the 7 day period of patch application.
Granisetron (Granisetron Transdermal System) is supplied as a 52 cm2 patch containing 34.3 mg of Granisetron. Each patch is printed on one side with the words "Granisetron 3.1 mg/24 hours". Each patch is packaged in a separate sealed foil-lined plastic pouch.
Granisetron is available in packages of 1 (NDC 42747-726-01) patch.
Store at 20°-25°C (68°-77°F); excursions permitted between 15°-30°C (59°-86°F)..
Granisetron should be stored in the original packaging.
Advise the patient to read the FDA-approved patient labeling
Because the use of Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition, patients should be instructed to tell their physician if they have pain or swelling in their abdomen.
Patients should be instructed to remove the patch if they have a severe skin reaction, or a generalized skin reaction.
When patients remove the patch, they should be instructed to peel it off gently.
Granisetron may be degraded by direct sunlight or exposure to sunlamps. In addition, an in vitro study using Chinese hamster ovary cells suggests that Granisetron has the potential for photogenotoxicity .
Patients must be advised to cover the patch application site, e.g. with clothing, if there is a risk of exposure to sunlight or sunlamps throughout the period of wear and for 10 days following its removal.
Advise patients of the possibility of serotonin syndrome with concomitant use of Granisetron and another serotonergic agent such as medications to treat depression and migraines. Advise patients to seek immediate medical attention if the following symptoms occur: changes in mental status, autonomic instability, neuromuscular symptoms, with or without gastrointestinal symptoms.
Patients should be advised not to apply a heat pad over or near the Granisetron patch. Patients should avoid prolonged exposure to heat as plasma concentration continues increasing during the period of heat exposure.
3M Delivery Systems
St. Paul, MN 55107
Kyowa Kirin, Inc.
Bedminster, NJ 07921
Copyright © 2017, Kyowa Kirin, Inc. All rights reserved.
Granisetron and Kyowa Kirin are trademarks owned by the Kyowa Kirin group of companies
(granisetron transdermal system)
|IMPORTANT: For skin use only|
Read the Patient Information that comes with Granisetron before you start using it and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. If you have any questions about Granisetron, ask your healthcare provider.
What is Granisetron?
Granisetron is a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment. Granisetron is a skin patch that slowly releases the medicine contained in the adhesive (glue), through clean and intact skin areas into your bloodstream while you wear the patch.
|Important: Granisetron contains Granisetron, the same medicine in Kytril. Do not take Kytril at the same time you use Granisetron unless your healthcare provider tells you it is alright.|
Who should not use Granisetron?
Do not use Granisetron if you are allergic to any of the ingredients in Granisetron. See the end of this leaflet for a list of ingredients in Granisetron.
What should I tell my healthcare provider before using Granisetron?
Tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Other medicines may affect how Granisetron works. Granisetron may also affect how other medicines work.
How should Granisetron be used?
Use Granisetron exactly as prescribed. See the detailed Patient Instructions for Applying Granisetron at the end of this Patient Information leaflet.
What should I avoid while using Granisetron?
Do not apply any heat source over or near the Granisetron patch. For example,
Avoid sunlight. The medicine in Granisetron (granisetron) may not work as well and/or may affect your skin if exposed to direct sunlight or the light from sunlamps or tanning beds. It is important to do the following:
What are the possible side effects of Granisetron?
Granisetron can cause serious side effects:
Common side effects of Granisetron are:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Granisetron. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Granisetron?
Keep Granisetron out of the reach of children.
General information about Granisetron
Medicines are sometimes prescribed for conditions that are not mentioned in Patient Information leaflets. Do not use Granisetron for a condition for which it is not prescribed. Do not give Granisetron to other people, even if they have the same symptoms you have. It may harm them.
This Patient Information leaflet summarizes the most important information about Granisetron. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about Granisetron that is written for health professionals.
For more information, go to www.sancuso.com or call 1-800-SANCUSO.
Patient Instructions for Applying Granisetron
When do I apply the Granisetron patch?
Where do I apply the Granisetron patch?
How do I apply the Granisetron patch?
The Granisetron patch comes inside a pouch which is inside the carton.
What to do if the Granisetron patch does not stick well?
If the patch does not stick well, you may use surgical bandages or medical adhesive tape to keep the patch in place. Place tape or bandages on the edges of the patch. Do not completely cover the patch with bandages or tape and do not wrap completely around your arm. If the patch comes more than half off or it becomes damaged see your healthcare provider.
Can I bathe or shower while wearing Granisetron?
You can continue to shower and wash normally while wearing the Granisetron patch. It is not known how other activities, for example swimming, strenuous exercise or using a sauna or whirlpool, may affect Granisetron. Avoid these activities while wearing Granisetron.
How do I remove and dispose of Granisetron?
What are the ingredients in Granisetron?
Active ingredient: Granisetron.
Inactive ingredients: acrylate-vinylacetate copolymer, polyester, titanium dioxide, polyamide resin and polyethylene wax.
3M Drug Delivery Systems, St. Paul, MN 55107
Kyowa Kirin, Inc., Bedminster, NJ 07921
Copyright © 2017 Kyowa Kirin, Inc. All rights reserved.
Granisetron and Kyowa Kirin are trademarks owned by the Kyowa Kirin group of companies
Image Image Image Image Image Image
|Apo-Granisetron 1 mg Tablet||14.14 USD|
|Granisetron hcl 0.1 mg/ml vial||7.2 USD|
|Granisetron hcl 1 mg tablet||60.19 USD|
|Granisetron hcl 4 mg/4 ml vial||24.0 USD|
|Injectable; Injection; Granisetron Hydrochloride 0.1 mg / ml|
|Injectable; Injection; Granisetron Hydrochloride 1 mg / ml|
|Kytril 0.1 mg/ml vial||11.54 USD|
|Kytril 1 mg tablet||20.27 USD|
|Kytril 2 1 mg tablet Box||131.98 USD|
|Sancuso 3.1 mg/24 hr patch||372.0 USD|
|Solution; Oral; Granisetron Hydrochloride 0.2 mg / ml|
|Tablets, Film-Coated; Oral; Granisetron Hydrochloride 1 mg|
|Tablets, Film-Coated; Oral; Granisetron Hydrochloride 2 mg|
|Tablets; Oral; Granisetron Hydrochloride 1 mg|
|Tablets; Oral; Granisetron Hydrochloride 2 mg|
Depending on the reaction of the Granisetron after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Granisetron not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Granisetron addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology